Back to list

Devoted Health

Tech-enabled Medicare Advantage insurer with in-house clinical care.
Healthcare 📍 Waltham, MA Founded 2017
Current Valuation
$13B
as of 2023-Q4
DECACORN

IPO Outlookrumored

Is Devoted Health going public in 2027?
An IPO is rumored for 2027, with nothing filed. Devoted Health remains private and the date is not the company's.
What is Devoted Health's valuation in 2026?
Devoted Health is valued at $13B as of 2023-Q4, set by its Series F-Prime ($317M, Jan 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Devoted Health filed an S-1?
No public S-1 is on file for Devoted Health as of 08/23/2026; the IPO is rumored.
Who are Devoted Health's investors?
Devoted Health's investors include Andreessen Horowitz, GIC, Premji Invest, Uprising, Maverick Ventures, Frist Cressey Ventures and 1 more.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Devoted Health is a tech-enabled Medicare Advantage insurer founded by Athenahealth co-founders Todd and Ed Park, combining a health plan with an in-house clinical group (Devoted Medical). Sacra-tracked revenue reached $3.27B in 2024, up 69% YoY.

Company Profile

CEO
Todd Park
Founded
2017
HQ
Waltham, MA
Employees
2000+
Total Raised
$3.0B
Est. Revenue
$3.3B (2024)
Growth
Serving over 466,000 members across 29 states as of January 2026, up 121% year over year, funded by $366M of fresh equity in two tranches (a $48M Series F in November 2025 and a $317M Series F-Prime in January 2026)
Last Round
Series F-Prime — $317M (Jan 2026)
IPO Status
rumored

Fundraising Status

Series F-Prime · $317M · 7 mo ago
rumoredTotal raised $3.0B

Secondary Market

Implied price / share
$35.51
Last round price / share
$56.25
vs last round
-36.9%
Open interest
1
Last round price vs secondary price
Last round vs current secondary price per share$56.25Last round$35.51Current
Secondary price return by period
Secondary market period returns3-month+11.2%6-month+11.1%1-year+11.1%All-time-35.4%
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series F-Prime$317MJan 2026

Talent Signal

Hiring trend
First snapshot
trend accrues with monthly sweeps
Open roles
71
via workday
Product-build share
31%
engineering, research, product, design
Trajectory
steady
balanced build + GTM — 31% builders vs 69% go-to-market/G&A — scaling both sides.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by month71Aug '26
Open roles by function
Open roles by functionOther41Clinical & Science19Ops & People4Engineering3Support2Sales & GTM1Finance & Strategy1
product-building   go-to-market / G&A
Bilingual (Spanish/English) Diabetes Educator - Clinical Guide(Certified DiabeteDiabetes Educator - Clinical Guide(Certified Diabetes Care and Education SpecialSupport EngineerSupport EngineerDirector, Clinical Pharmacy Stars PerformanceCollaborating Physician Contractor-Georgia
Counted from Devoted Health's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.

Founders & Key People

Ed ParkTodd Park

Investors

Andreessen Horowitz · GIC · Premji Invest · Uprising · Maverick Ventures · Frist Cressey Ventures · ICONIQ Capital

Products

  • Devoted Health Medicare Advantage plans
  • Devoted Medical (in-house clinical group)
  • Member-facing digital health platform

Competitors

Humana · UnitedHealth (Optum) · Clover Health · Alignment Healthcare · Bright Health
HealthTechInsuranceMedicare AdvantageTelehealthUnicorn
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2023-Q4. Refreshed quarterly.